Bryan Garnier - Cleantech Energy transition: Q3 results are correct but does it really matter ? No. All eyes are on the deal with Veolia

Report

Bryan Garnier

Xavier Regnard

Cleantech & Energy transition: Q3 results are correct but does it really matter ? No. All eyes are on the deal with Veolia

Cleantech & Energy transition
Q3 results are correct but does it really matter ? No. All eyes are on the deal with Veolia

Q3 results are correct but the visibility is still limited
Guidance confirmed. Too optimistic ?
Anyway, results don’t matter, all eyes are on the deal with Veolia
The situation is uncomfortable for Veolia too

29/10/2020 4 EN

Provider

Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

See profile

Analysts

Xavier Regnard

Other Reports from Bryan Garnier

Oscar Haffen Lamm

Oscar Haffen Lamm

Cinclus Pharma: Q2 driven by BD progress, Phase 3 trial nearing initiation

Cinclus’ Q2 update focused on balance sheet items and a recap of corporate achievements. The company reported a cash position of SEK589m and operating expenses of SEK80.9m, up from the prior quarter - consistent with expectations given the Phase 3 trial ramp-up. With support from the Zentiva partne

20h / 51m 20h / 51m 1 EN

Oscar Haffen Lamm

Oscar Haffen Lamm

Egetis: Submits pre-NDA meeting, positive recruitment update

Egetis posted a positive US development update on Emcitate with 15 evaluable patients in the US ReTRIACt phase 3 study (vs 12 at previous update) and has submitted a pre-NDA meeting (Type B) request to the FDA, with plans to initiate the submission of the NDA for tiratricol (Emcitate) this year. As

August 18, 2025 August 18, 2025 1 EN

Damien Choplain ... (+2)

Damien Choplain
Oscar Haffen Lamm

Faron: Positive FDA feedback sends BEX into a registrational phase 2/3 study

Faron is advancing bexmarilimab (BEX) into a registrational phase 2/3 trial in HR-MDS following a positive EOP2 meeting with the FDA. We view the feedback of broadly positive, as the trial design remains largely unchanged, with a single study expected to support approvals in both frontline and rela

August 18, 2025 August 18, 2025 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Cleantech & Energy transition: Q3 results are correct but does it really matter ? No. All eyes are on the deal with Veolia

Cinclus Pharma: Q2 driven by BD progress, Phase 3 trial nearing initiation

Egetis: Submits pre-NDA meeting, positive recruitment update

Faron: Positive FDA feedback sends BEX into a registrational phase 2/3 study

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe